Search
Evalstotug
go.drugbank.com/drugs/DB19410InvestigationalEvalstotug is under investigation in clinical trial NCT05271604 (A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck).
ABT-639
go.drugbank.com/drugs/DB15055InvestigationalABT-639 is under investigation in clinical trial NCT01345045 (A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain).
Mibenratide
go.drugbank.com/drugs/DB15195InvestigationalMibenratide is under investigation in clinical trial NCT01798745 (A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic
TERN-101
go.drugbank.com/drugs/DB16045InvestigationalTERN-101 is under investigation in clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis
Edivoxetine
go.drugbank.com/drugs/DB09184InvestigationalEdivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012. … Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant
Sabatolimab
go.drugbank.com/drugs/DB16322InvestigationalSabatolimab is under investigation in clinical trial NCT03946670 (A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic
Bleselumab
go.drugbank.com/drugs/DB15253InvestigationalBleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney
SYNB1020
go.drugbank.com/drugs/DB17667Investigationaldiscontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. … It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer
Basroparib
go.drugbank.com/drugs/DB21582InvestigationalBasroparib is under investigation in clinical trial NCT04505839 (First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors). … The usage of the INN stem '-parib' in the name indicates that Basroparib is a poly-ADP-Ribose polymerase inhibitor.
Gabexate
go.drugbank.com/drugs/DB12831InvestigationalGabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis.[A19218,A19219,A19220] … Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines.